- $137.40m
- $131.64m
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment
Brief: Enlivex Therapeutics Reaffirms August 18, 2025 As Target Date For Announcement Of Phase II Topline Data
Brief: Enlivex Announces The Dosing Of The First Patient In A Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis
Brief: Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra™ Trial In Knee Osteoarthritis
Enlivex falls after interim data for joint disease cell therapy
Brief: Enlivex Announces The Dosing Of The First Patient In A Phase I Clinical Trial Evaluating Allocetra In Patients With Psoriatic Arthritis
Brief: Enlivex Announces The Enrollment And Dosing Of The First 10 Patient In The Randomized Phase II Stage Of Its Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis
Brief: Enlivex Receives Notice Of Allowance For Japanese Patent Application Covering The Use Of Allocetra In Patients With Osteoarthritis
Brief: Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Brief: Enlivex Gets Israel Approval For Phase I Clinical Trial Of Allocetra For Psoriatic Arthiritis
Brief: Enlivex Announces The Dosing Of The First Patient In A Phase I/II Trial Evaluating AllocetraTM In Patients With Thumb Osteoarthritis
Brief: Enlivex Announces Interim Data From Phase I/II trial Evaluating Allocetra In End-Stage Knee Osteoarthritis
Brief: Enlivex Announces Authorization From The Danish Regulatory Agency For Its Randomized, Controlled Phase I/II Trial
Enlivex Therapeutics sinks after mid-stage study data for lead therapy
Brief: Enlivex Announces Topline Results Of Phase II Trial Evaluating Allocetra In Patients With Sepsis
Brief: Enlivex Announces Completion Of Enrollment Of Its Phase Ii Trial Evaluating Allocetra In Patients With Sepsis